Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autotransplantation in multiple myeloma

D H Vesole1, S Jagannath, L Glenn

  • 1Department of Medicine, University of Arkansas for Medical Sciences, Little Rock.

Hematology/Oncology Clinics of North America
|June 1, 1993
PubMed
Summary

High-dose chemotherapy with autologous stem cell transplant is effective for multiple myeloma. Tandem transplants show low risk, especially in patients with less prior treatment and sensitive disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between child marriage and high blood glucose level in women: A birth cohort analysis.

Public health in practice (Oxford, England)·2024
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Drug response prediction in high-risk multiple myeloma.

Gene·2017
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Multiple myeloma is a hematologic malignancy.
  • High-dose chemotherapy with stem cell rescue is a key treatment modality.
  • Treatment strategies continue to evolve.

Purpose of the Study:

  • To review the efficacy of high-dose chemotherapy and autologous hematopoietic stem cell reconstitution in multiple myeloma.
  • To discuss preparative regimens, stem cell sources, and post-transplant immunomodulation.
  • To highlight patient subgroups with the most favorable outcomes.

Main Methods:

  • Review of existing literature on high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.
  • Discussion of preparative regimens, stem cell sources, and immunomodulatory strategies.

Related Experiment Videos

  • Analysis of factors influencing treatment outcomes, including prior treatment, tumor burden, and disease sensitivity.

    • Main Results:

    • High-dose chemotherapy with autologous stem cell reconstitution demonstrates efficacy in multiple myeloma treatment.
    • Tandem autotransplantation with melphalan chemotherapy exhibits low morbidity and mortality, even in refractory disease.
    • Optimal outcomes are associated with less prior therapy, lower tumor burden, and sensitive disease.

    Conclusions:

    • Autologous stem cell transplantation is a valuable therapeutic option for multiple myeloma.
    • Tandem transplantation is a safe and effective approach, particularly for specific patient populations.
    • Patient selection and disease characteristics are critical for maximizing treatment success.